openPR Logo
Press release

Dr. Pratap Singh, to Discuss PK/PD Modeling Analysis of a Compound Targeting Muscle Growth in Rosa’s Impact Webinar Series

10-10-2012 07:50 PM CET | Science & Education

Press release from: Rosa and Co

Rosa Logo

Rosa Logo

Dr. Singh, will present “Role of Myostatin in Muscle Growth: Key Learnings From PK/PD Modeling Analysis” Webinar October 17, 2012.

Rosa & Co. LLC today announced that Dr. Pratap Singh, Senior Principal Scientist at Pfizer, will present a webinar “Role of Myostatin in Muscle Growth: Key Learnings From PK/PD Modeling Analysis” on Wednesday, October 17, 2012 at 1:00 - 2:00 pm EDT as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development,” is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs.

According to Dr. Singh, “Suppression of the myostatin (GDF-8) pathway is considered an important therapeutic strategy for the treatment of muscle-wasting disorders, including muscular dystrophy, cachexia and sarcopenia. Myostatin is a member of TGF-β superfamily and negatively regulates skeletal muscle mass, muscle fiber size, and fiber count. Clinical trials targeting the myostatin pathways have produced mixed results. ACE-031, a Fc fusion of ActRIIB, is a decoy receptor for GDF-8. ACE-O31 was reported to increase muscle mass in Phase I/II trials with healthy post-menopausal women and in patients with Duchenne muscular dystrophy (DMD). In contrast, an antibody against myostatin, MYO-029, failed to achieve clinical efficacy in DMD patients. Given these contrasting results, it is critical to understand whether the clinical and preclinical data support GDF-8 as a novel paradigm for the treatment of muscular dystrophy disease. We performed a detailed pharmacokinetic-pharmacodynamic (PK/PD) analysis of preclinical and clinical data on MYO-029 to address animal model translation and predict the level of target inhibition at the clinical doses. A combination of mouse, non-human primates, and clinical data were analyzed, and exposure-response relationships were established for various pharmacodynamic endpoints. These included muscle weight increase in SCID mice efficacy studies, muscle circumference changes in a 39-week toxicology study in monkeys, and total myostatin levels observed in multiple-ascending dose (MAD) studies in Phase I/II trials. Our modeling analysis revealed a significant, in-vivo potency shift between mice and monkeys species. Further, our results showed that the exposures of Myo-029 in humans had low probability of success in modulating the target or in providing robust efficacy. The PK/PD analysis presented in this report supported the rationale for therapeutic strategies targeting the myostatin pathway.”

Register for this free webinar at http://www.rosaandco.com/webinar. After registering, a confirmation email will be sent with directions for joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at http://www.rosaandco.com/webinar.

About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals.

More information can be found online at http://www.rosaandco.com

Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dr. Pratap Singh, to Discuss PK/PD Modeling Analysis of a Compound Targeting Muscle Growth in Rosa’s Impact Webinar Series here

News-ID: 238959 • Views:

More Releases for PK/PD

2019 Lateat Bioanalytical Testing Services Market Growth Analysis by Test Type-P …
Global Bioanalytical Testing Services Market is expected to touch a valuation of USD 1,867.30 million by 2023, as per the latest report by Market Research Future (MRFR). High needs of blockbuster drugs to treat chronic diseases is one of the major factors predicted to drive the market growth over the forecast period (2018-2023). Rising research and development activities conducted in biotechnology and pharmaceutical sectors can spur market growth. Rising prevalence of
Bioanalytical Testing Services Market by ADME, PK, PD, Bioavailability, Bioequiv …
This report studies the global Bioanalytical Testing Services market, analyzes and researches the Bioanalytical Testing Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like PPD ICON plc. Covance Inc. LabCorp Charles River Laboratories International, Inc. inVentiv Health SGS SA Toxikon, Inc. Intertek group Pace Analytical Services, LLC Get the sample copy of report @ https://www.marketresearchreports.biz/sample/sample/1481393 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment
Dr. Toufigh Gordi to discuss the Selection of Appropriate Mathematical Modeling …
Dr. Gordi, will discuss choice of models and their Impact in the Drug Development Process on November 28, 2012 in Frankfort, Germany Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Dr. Toufigh Gordi, President of PK/PD and Clinical Pharmacology Services, will present a talk at the 4th World PK/PD Summit on November 28, 2012, in Frankfort, Germany. The talk, entitled
Rosa to Present Systems Pharmacology Workshop at 3rd Annual World PK/PD Summit
Rosa Workshop Presents The MQM Quality Standard For Mechanistic Modeling Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a pre-conference workshop entitled “Development of Mechanistic Systems Pharmacology Modeling for Insight and Decision Support” on Tuesday, 27 March 2012, as part of the 3rd Annual World PK/PD Summit, March 27 – 29, 2012 in Boston. Dr. Christina Friedrich
Rosa PK/PD Collaboration with Pfizer to be Presented at ASCPT 2012
PK/PD analyses used to support the rationale for therapeutic strategies targeting myostatin pathway Rosa & Co. LLC, a drug development advisory firm with expertise in PK/PD and drug-disease modeling and simulation, today announced that results from its PK/PD collaboration with Pfizer will be presented as a poster at the 2012 American Society for Clinical Pharmacology and Therapeutics annual meeting in National Harbor, Maryland. The poster entitled "Role of Myostatin Pathway in
Dr. Hartmut Derendorf to Discuss PK/PD-based Drug Development in Rosa’s World- …
Rosa & Co. LLC today announced that Dr. Hartmut Derendorf, University of Florida, Gainesville, will present a webinar “PK/PD-based Development of Anti-infective Agents” on Monday, February 13, 2012 at 1:00 to 2:00 pm EST as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics,